Cape Town
South Africa
Tuberculosis; TB; drug-sensitive tuberculosis; DS-TB; MDR-TB; multidrug-resistant TB; regimen development; pretomanid, moxifloxacin, pyrazinamide; ethambutol; HRZE, phase 3 clinical trial; PaMZ
maximum tolerable dose; high-dose rifampicin; pharmacokinetics; early bactericidal activity; dose optimization; exposure-response